Aurinia Pharmaceuticals (AUPH) said Japan's Ministry of Health, Labor and Welfare approved voclosporin in combination with mycophenolate mofetil to treat lupus nephritis.
The approval is based on efficacy and safety data of voclosporin, which is available in the US under the brand name Lupkynis, Aurinia said Tuesday in a statement.
The company said its collaboration partner, Otsuka Pharmaceutical, filed the new drug application in Japan in November.
Price: 6.84, Change: -0.14, Percent Change: -2.02
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments